Circulation Research. 1995;77:530-535
(Circulation Research. 1995;77:530-535.)
© 1995 American Heart Association, Inc.
Elevated Levels of cAMP Inhibit Protein Kinase C Independent Mechanisms of Endothelial Platelet-Derived Growth FactorB Chain and Intercellular Adhesion Molecule-1 Gene Induction by Lysophosphatidylcholine
Hiroshi Ochi,
Noriaki Kume,
Eiichiro Nishi,
Toru Kita
From the Department of Geriatric Medicine, Faculty of Medicine, Kyoto
University, Japan.
Correspondence to Noriaki Kume, MD, PhD, Department of Geriatric Medicine, Faculty of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606, Japan.
 |
Abstract
|
|---|
Abstract Lysophosphatidylcholine (lyso-PC), a polar
phospholipid
product increased in atherogenic lipoproteins and
atherosclerotic
lesions, has been shown to differentially induce
functional
intercellular adhesion molecule-1 (ICAM-1) and vascular cell
adhesion
molecule-1 and mRNA for platelet-derived growth factor
(PDGF)A
and B chains and heparin-binding epidermal growth
factorlike
growth factor in various cultured
endothelial cells. In this
study, we have demonstrated
increased expression of cell- and
matrix-associated forms of PDGFB
chain (PDGF-B) protein
elicited by lyso-PC and further characterized
potential signal
transduction mechanisms responsible for
lyso-PCinduced
gene expression, focusing on PDGF-B and ICAM-1 genes
in cultured
human umbilical vein endothelial cell
models. Cycloheximide
almost completely inhibited PDGF-B but not ICAM-1
mRNA induction
elicited by lyso-PC, suggesting that dependence on de
novo protein
synthesis for PDGF-B is different from that for ICAM-1.
Prolonged
exposure to phorbol myristate acetate (PMA), which
depletes
protein kinase C (PKC), or staurosporine, a PKC
inhibitor, did
not block lyso-PCinduced increases in
PDGF-B or ICAM-1
mRNA. Forskolin and dibutyryl cAMP, which elevate
intracellular
cAMP levels, blocked both PDGF-B and ICAM-1 upregulation
elicited
by lyso-PC; however, these cAMP-elevating agents did not
suppress
ICAM-1 upregulation by PMA. Taken together, PDGF-B and ICAM-1
gene
induction by lyso-PC may involve different signaling mechanisms;
however,
both appear to be independent of PMA-regulatable PKC
activation
but are suppressed by increased levels of intracellular
cAMP.
Key Words: protein kinase C platelet-derived growth factorB chain intercellular adhesion molecule-1 cAMP lysophosphatidylcholine
 |
Introduction
|
|---|
Vascular
endothelium plays a pivotal role in the pathogenesis
of
vascular diseases, including atherosclerosis and
inflammation,
expressing endothelial-leukocyte adhesion
molecules, growth
factors, and cytokines in response to various
pathophysiological
stimuli.
1 2 3 Lyso-PC, which is a prominent phospholipid component
of
atherogenic lipoproteins
4 and is also generated in
inflammatory
lesions by extracellular phospholipase A
2
activities,
5 has
been shown to differentially upregulate
VCAM-1 and ICAM-1 expression
in various cultured
endothelial cells, showing its potential
role in
mononuclear leukocyte recruitment into these lesions.
6
Lyso-PC has been demonstrated to induce gene expression of
potent
smooth muscle growth factors such as PDGFA and
B chains and HB-EGF
in cultured human endothelial cells,
thus suggesting
its potential role in smooth muscle proliferation.
7
Lyso-PC has been shown to act on human monocytes as well to
induce
HB-EGF gene expression.
8 These effects of lyso-PC on
endothelial
genes appear to be specific and distinct
from those elicited
by cytokines, such as IL-1 and TNF-

,
since neither E-selectin
nor IL-8 was upregulated in the same cells
stimulated with lyso-PC.
Nuclear runoff assays and the evaluation of
mRNA half-lives
have indicated that lyso-PC stimulates transcription of
these
genes
7 ; however, signal transduction mechanisms
responsible
for the gene induction of adhesion molecules and growth
factors
by this lyso-PC stimulus have not been fully elucidated.
Furthermore,
the effects of lyso-PC on growth factor protein expression
have
not been determined in cultured endothelial
cells.
In the present study, therefore, we have measured PDGF-B protein
levels in lyso-PCtreated cultured HUVECs and explored the
potential signal transduction mechanisms involved in both PDGF-B and
ICAM-1 upregulation elicited by lyso-PC, focusing on roles of PKC and
cAMP.
 |
Materials and Methods
|
|---|
Cells
Cultured HUVECs were isolated by collagenase
digestion and grown
in medium 199 with 20% (vol/vol)
heat-inactivated FBS (Irvine
Scientific), supplemented with
100 U/mL penicillin, 100 mg/mL
streptomycin, 25 U/mL heparin (porcine
intestinal mucosa, Sigma
Chemical Co), and 30 mg/mL ECGS (Sigma) as
previously described.
9 All experiments were carried out
within 3 days after HUVECs
reached confluence. Cells (passage numbers
between 2 and 4)
were incubated with or without test stimuli in medium
199 supplemented
with 5% (vol/vol) FBS, without heparin or ECGS.
Reagents
Lyso-PC (palmitoyl, C16:0) was purchased from Avanti Polar
Lipids. Cycloheximide, PMA, forskolin, and Bt2cAMP were
obtained from Sigma, and staurosporine was from Calbiochem.
All other reagents were of reagent grade.
Northern Blot Analysis
Total cellular RNA, isolated from HUVECs by the acid
guanidiniumphenolchloroform method,10 was
electrophoresed through 1% agarose gels containing formaldehyde,
transferred onto 0.45-µm nylon membranes (Zeta-Probe, Bio-Rad), and
fixed by UV cross-linking. Northern membranes were hybridized with
human ICAM-1 and PDGF-B cDNA probes, which were labeled with
[
-32P]dCTP (DuPont NEN) by using random
hexanucleotide primers (Pharmacia) at 65°C for 18
hours in a mixture containing 1 mmol/L EDTA, 0.25 mol/L
Na2HPO4 (pH 7.2), and 7% SDS. The filters were
subsequently washed at 65°C twice with 1 mmol/L EDTA, 40 mmol/L
Na2HPO4 (pH 7.2), and 5% SDS and once with 1
mmol/L EDTA, 40 mmol/L Na2HPO4 (pH 7.2), and
1% SDS and exposed to x-ray films. A 1.3-kb Xho I fragment
of human ICAM-1, kindly provided by Dr Brian Seed (Massachusetts
General Hospital, Boston), was used to detect ICAM-1
mRNA.6 7 11 A 2.1-kb BamHI fragment of human
PDGF-B cDNA,12 obtained from American Type Culture
Collection, and a Pst IEcoRI fragment of human
PDGF-B,13 kindly provided by Dr Tucker Collins (Brigham
and Women's Hospital, Boston, Mass) were used as hybridization probes.
Northern analyses using these PDGF-B cDNAs gave similar
results. Some blots were rehybridized with radiolabeled human ß-actin
cDNA to control the amounts of RNA loaded. Densitometric scanning was
performed to quantify the amounts of mRNA; an Image Master laser
densitometer (Pharmacia) was used. Relative amounts of mRNA for PDGF-B
and ICAM-1 were normalized to ß-actin mRNA levels.
Western Blot Analysis
Laemmli sample buffer (2% SDS, 10% glycerol, 60 mmol/L Tris
[pH 6.8], and 0.001% bromophenol blue) was directly poured into
HUVEC culture plates, and the cell lysates were passed through 25-gauge
needles 10 times. After heating at 98°C for 10 minutes, samples were
subjected to SDSpolyacrylamide (10% to
20% gradient) gel
electrophoresis in nonreducing conditions and transferred onto
nitrocellulose filters (Hybond ECL filters, Amersham Corp) by
electroblotting. After preincubation with TBS (50 mmol/L Tris-Cl [pH
8.0], 2 mmol/L CaCl2, 100 mmol/L NaCl, and 5%
[wt/vol] nonfat dry milk) for 3 hours at room temperature, filters
were incubated with a rabbit polyclonal antibody directed to PDGF-BB
homodimer (Genzyme Corp) diluted in TBS at room temperature for 2
hours, followed by washing twice with TBS without nonfat dry milk.
Filters were then incubated with the horseradish peroxidaseconjugated
anti-rabbit IgG antibody (Amersham) diluted in TBS for 2 hours at room
temperature, washed twice in TBS without nonfat dry milk, and
visualized by use of a chemiluminescence reagent (ECL kit, Amersham
Corp).
Statistical Analysis
Statistical analyses were carried out by paired
Student's t test. Percent changes in mRNA levels compared
with respective controls are expressed as mean±SD.
 |
Results
|
|---|
Lyso-PC Induces Cell- and Matrix-Associated Forms of PDGF-B
Protein
Lyso-PC has been shown to increase the amounts of mRNA
for PDGF-B.
7 To examine the effects of lyso-PC on PDGF-B
protein levels,
we performed Western blot analyses using cell
lysate from lyso-PCtreated
HUVECs. As shown in Fig 1

, multiple bands with approximate molecular
masses
between 38 and 43 kD, which appear to be compatible with
previous
reports,
14 15 16 were detected by treatments with
lyso-PC for
8 hours and continuously increased for at least
20 hours. Similar bands
of 38 to 45 kD were detectable in HUVECs
treated with PMA for 8 hours.
These bands disappeared when excess
amounts of recombinant human
PDGF-BB homodimer were included
in the incubation buffer containing
anti-human PDGF-B antibody
(data not shown). Two additional bands with
approximate molecular
masses of 85 and 55 kD, respectively, appeared to
be nonspecific,
since these bands were similarly detectable when
anti-human
PDGF-B was replaced at a concentration equivalent to that of
nonimmune
rabbit serum (data not shown).

View larger version (83K):
[in this window]
[in a new window]
|
Figure 1. Time course of PDGF-B protein expression induced by
lyso-PC. Confluent monolayers of HUVECs were treated with or without
test reagents (100 nmol/L PMA or 70 µmol/L lyso-PC in medium 199 with
5% FBS) for the indicated times. Cell lysate was subjected to Western
blot analyses as described in "Materials and Methods."
Recombinant human (rh) PDGF-BB (5 ng per lane, Genzyme Corp) dissolved
in Laemmli buffer was also included as a reference. Molecular mass
standards (in kilodaltons) are indicated on the left. One of three
similar results is shown. * denotes bands for PDGF-B.
|
|
PDGF-B mRNA Upregulation by Lyso-PC Depends on De Novo Protein
Synthesis, but ICAM-1 Does Not
In previous studies, lyso-PC has been shown to upregulate mRNA for
both ICAM-1 and PDGF-B as early as 4 hours of treatment. To determine
whether de novo protein synthesis is required in this process, we
treated HUVECs with or without lyso-PC (or PMA as a control) in the
presence or absence of cycloheximide for 4 hours, and Northern blot
analyses were performed. Cycloheximide completely blocked
lyso-PCinduced, as well as PMA-induced, increases in PDGF mRNA
levels, although cycloheximide alone modestly increased the amount of
PDGF-B mRNA (Fig 2A
). In contrast, cycloheximide
dramatically increased ICAM-1 mRNA levels in both untreated and
lyso-PCtreated or PMA-treated cells (Fig 2B
). These results clearly
indicate that dependence of de novo protein synthesis in
lyso-PCinduced, as well as PMA-induced, gene upregulation is
different between PDGF-B and ICAM-1.

View larger version (96K):
[in this window]
[in a new window]
|
Figure 2. Dependence of PDGF-B and ICAM-1 mRNA induction by
lyso-PC or PMA on de novo protein synthesis. Confluent monolayers of
HUVECs were treated for 4 hours with media alone, lyso-PC (60
µmol/L), or PMA (100 nmol/L) in the presence (+) or absence (-) of
cycloheximide (10 µg/mL). Total cellular RNA was isolated, and
Northern blot analyses were performed as described in
"Materials and Methods" to detect PDGF-B mRNA (A) and ICAM-1 mRNA
(B). Each lane contained 10 µg total RNA. One of two similar results
is shown.
|
|
Induction of mRNA for Both PDGF-B and ICAM-1 Is Independent of
PMA-Regulatable PKC Activation
To investigate the potential role of PKC in PDGF-B and ICAM-1 mRNA
induction by lyso-PC, we followed two strategies: depletion of PKC
activities by prolonged exposure to PMA and inhibition of PKC by a
pharmacological reagent. As shown in Fig 3
, pretreatment
with PMA for 24 hours significantly blocked PDGF-B mRNA induction
elicited by the subsequent stimulation with PMA (63±18% reduction);
however, this PMA pretreatment did not inhibit lyso-PCinduced
increases in PDGF-B mRNA. Effects of prolonged exposure to PMA on
ICAM-1 mRNA upregulation is similar to those observed in PDGF-B;
pretreatment with PMA did not prohibit lyso-PCinduced increases in
ICAM-1 mRNA levels but completely blocked the effect of the subsequent
stimulation with PMA (>99% reduction). We also examined the effects
of staurosporine, an inhibitor of PKC.
Staurosporine (10 nmol/L) significantly reduced PMA-induced
increases in PDGF-B mRNA levels (44±12% reduction); however, this
agent did not inhibit but rather increased those elicited by lyso-PC
(Fig 4
). These results indicate that signal transduction
mechanisms responsible for PDGF-B and ICAM-1 mRNA upregulation elicited
by lyso-PC in HUVECs appear to be dissociated from PMA-regulatable PKC
activation. We further tested the effects of higher concentrations of
staurosporine; however, >50 nmol/L concentrations of this
reagent with 60 µmol/L lyso-PC caused morphologically apparent
cytotoxicity.

View larger version (41K):
[in this window]
[in a new window]
|
Figure 3. Effect of prolonged exposure to PMA on PDGF-B and
ICAM-1 mRNA levels. Confluent monolayers of HUVECs were pretreated with
(+) or without (-) PMA (500 nmol/L in 5% FBS/medium 199) for 24 hours
and subsequently incubated with lyso-PC (60 µmol/L) or PMA (100
nmol/L) for 4 hours. Northern blot analyses were carried out to
measure PDGF-B (A) and ICAM-1 (B) mRNA levels. Each lane contained 10
µg total RNA. Relative amounts of mRNA were calculated as described
in "Materials and Methods" (C). Mean values from four separate
experiments are shown. **P<.001 vs respective controls
without PMA pretreatment (solid bars).
|
|

View larger version (42K):
[in this window]
[in a new window]
|
Figure 4. Effects of staurosporine on PDGF-B mRNA
levels induced by lyso-PC or PMA. Confluent monolayers of HUVECs were
treated with media alone, lyso-PC (100 µmol/L), or PMA (100 nmol/L)
in the presence (+) or absence (-) of staurosporine (10
nmol/L) for 4 hours. Total cellular RNA was isolated from each sample,
and Northern blot analyses were performed as described. Each
lane contained 10 µg total RNA. A, One of four separate experiments
is shown. B, Relative amounts of PDGF-B mRNA were calculated as
described in "Materials and Methods." Mean values from four
separate experiments are shown. **P<.001 vs respective
controls without staurosporine (solid bars).
|
|
Elevated Levels of cAMP Inhibit PDGF-B and ICAM-1 mRNA Induction
Elicited by Lyso-PC
To explore the potential role of cAMP in lyso-PCinduced PDGF-B
and ICAM-1 gene expression, we examined the effects of forskolin and
Bt2cAMP, both of which can increase intracellular cAMP
levels. We treated HUVECs with or without lyso-PC or PMA in the
presence or absence of forskolin and measured mRNA levels for PDGF-B
and ICAM-1 by Northern analyses. As shown in Fig 5
, forskolin significantly reduced lyso-PCinduced, as
well as PMA-induced, increases in PDGF-B mRNA (59±19% and 68±19%
reduction, respectively). In contrast, this agent inhibited only
lyso-PCinduced increases in ICAM-1 mRNA (67±22% reduction) and did
not significantly block those induced by PMA. Bt2cAMP
exhibited effects similar to those observed with forskolin. Upregulated
expression of PDGF-B mRNA elicited by lyso-PC, as well as PMA, was
significantly prohibited by Bt2cAMP (54% and 30%
reduction, respectively); however, this agent blocked only
lyso-PCinduced ICAM-1 mRNA upregulation (46% reduction) but did not
show any significant inhibitory effect on PMA-induced
ICAM-1 mRNA expression (Fig 6
). To examine whether
elevated levels of cAMP decrease PDGF-B protein levels, we performed
Western blot analyses. Treatment with optimal doses of lyso-PC
or PMA for 20 hours significantly increased the levels of cell- and
matrix-associated forms of PDGF-BB, which were effectively suppressed
by forskolin (Fig 7
).

View larger version (41K):
[in this window]
[in a new window]
|
Figure 5. Effects of forskolin on PDGF-B and ICAM-1 mRNA
levels induced by lyso-PC or PMA. Confluent monolayers of HUVECs were
treated with media alone, lyso-PC (100 µmol/L), or PMA (100 nmol/L)
in the presence (+) or absence (-) of forskolin (25 µmol/L) for 4
hours. Total cellular RNA (12 µg per lane) was subjected to Northern
blot analyses. Representative results for
PDGF-B (A) and ICAM-1 (B) mRNA are shown. PDGF-B and ICAM-1 mRNA levels
were semiquantified as described in "Materials and Methods" (C).
Mean values from three (for ICAM-1) and five (for PDGF-B) separate
experiments are shown. *P<.05 and **P<.001 vs
respective controls without forskolin (solid bars).
|
|

View larger version (44K):
[in this window]
[in a new window]
|
Figure 6. Effects of Bt2cAMP on PDGF-B and ICAM-1
mRNA induction by lyso-PC or PMA. Confluent monolayers of HUVECs were
treated for 4 hours with lyso-PC (60 µmol/L) or PMA (200 nmol/L) in
the presence (+) or absence (-) of Bt2cAMP (1 mmol/L).
Northern blot analyses were performed as described in Fig 5 .
One of two similar results is shown (A). Densitometric analyses
were performed as described in "Materials and Methods" (B). Solid
bars indicate control (without Bt2cAMP).
Representative data from two separate experiments are
indicated.
|
|

View larger version (57K):
[in this window]
[in a new window]
|
Figure 7. Effects of forskolin on PDGF-B protein expression
induced by lyso-PC or PMA. HUVECs were treated for 20 hours with or
without test reagents (200 nmol/L PMA and 60 or 70 µmol/L lyso-PC) in
the presence or absence of forskolin (50 µmol/L). Cell lysate was
subjected to Western blot analyses as described in Fig 1 . One
of two similar results is shown. * denotes bands for PDGF-B.
|
|
We also have examined the effects of combinations of reagents used in
the present study on cell viability. We did not detect any evidence
of cytotoxicity by either microscopic observation or measuring lactate
dehydrogenase released into culture media (data not shown).
 |
Discussion
|
|---|
Endothelial expression of smooth muscle growth
factors and endothelial-leukocyte
adhesion molecules
appears to play an important role in atherogenesis
and inflammatory
disease processes.
1 2 3 Lyso-PC, a phospholipid
stimulus
relevant to atherosclerosis and inflammation, has been
shown
to selectively upregulate gene expression of adhesion molecules
and
growth factors, including PDGF-B and ICAM-1. In the present
study,
we have shown, for the first time, that cell- and
matrix-associated
forms of PDGF-B protein are increased by lyso-PC
treatment in
HUVECs. We have also explored the potential signal
transduction
mechanisms responsible for the PDGF-B and ICAM-1
upregulation
by lyso-PC in HUVEC models.
Inhibition of nascent protein synthesis by cycloheximide provided
contrasting results between PDGF-B and ICAM-1 gene regulation.
PDGF-B mRNA induction by lyso-PC, as well as that elicited by PMA,
requires de novo protein synthesis, but ICAM-1 does not. In fact,
cycloheximide enhanced the accumulation of ICAM-1 mRNA in both
lyso-PCtreated and untreated HUVECs; this finding appears to be
similar to the previous finding with PMA-treated and TNF-
treated
HUVECs.17 These results clearly indicate that signal
transduction mechanisms responsible for lyso-PCinduced gene
expression might be different between PDGF-B and ICAM-1.
PKC activation has been reported to be involved in lyso-PCinduced
inhibition of endothelium-dependent vasorelaxation ex
vivo, and transient activation of PKC has been detected in
lyso-PCstimulated endothelial cells.18
Furthermore, a recent report has shown that lyso-PC treatment resulted
in increased expression of ICAM-1 protein in isolated porcine
coronary arteries, which was efficiently blocked by PKC
inhibitors.19 Therefore, we have explored the
potential role of PKC in lyso-PCinduced endothelial
gene upregulation of PDGF-B and ICAM-1 in our HUVEC models, in which
selective patterns of gene regulation by lyso-PC have been well
characterized.7 Data presented here have clearly
demonstrated that upregulated expression of PDGF-B and ICAM-1 by
lyso-PC in our HUVEC models appears to depend on mechanisms other than
PMA-regulatable PKC activation. Previous studies by others, using PMA
and staurosporine, have indicated that ICAM-1 upregulation
by TNF-
also is dissociated from PKC activation,20 21
thus supporting the existence of PKC-independent mechanisms of ICAM-1
gene induction.
Transient increases in cytosolic calcium levels and turnover of
phosphoinositides have been detected in
lyso-PCtreated cultured endothelial cells and are
reported to be involved in the inhibitory actions of
lyso-PC on endothelium-dependent
vasorelaxation.22 Our preliminary experiments, however,
have revealed that the calcium ionophore ionomycin did not induce
PDGF-B or ICAM-1 mRNA (data not shown), suggesting that calcium
mobilization alone is not sufficient to induce
endothelial genes such as PDGF-B and ICAM-1.
The cAMPprotein kinase A pathway is another possible signal
transduction cascade that can transmit biological signals. Forskolin or
Bt2cAMP, which elevates intracellular cAMP levels, alone
did not upregulate PDGF-B or ICAM-1 expression but rather suppressed
lyso-PCinduced increases in both PDGF-B and ICAM-1 mRNA levels. These
effects of cAMP-elevating agents do not appear to result from general
inhibitory action, since forskolin or Bt2cAMP
inhibited lyso-PCinduced ICAM-1 mRNA upregulation but did not affect
that induced by PMA. Although previous studies by others have
demonstrated that elevated levels of intracellular cAMP can also
antagonize the effects of thrombin or TGF-ß on PDGF-B mRNA
levels23 but do not suppress ICAM-1 expression induced by
TNF-
,24 our results appear to be the first to
demonstrate that elevated levels of cAMP can counteract the effect of
lyso-PC on both PDGF-B and ICAM-1 expression.
Previous studies with Northern analyses using actinomycin D and
nuclear runoff assays have revealed that lyso-PC does not appear to act
on PDGF-B and ICAM-1 genes by stabilizing mRNA but rather by
stimulating gene transcription.7 Consensus sequences for
binding of known transcription factors, including activating protein 1
(AP-1), have been detected in 5' promoter regions of
PDGF-B25 26 27 and the ICAM-128 29 gene. Studies
are in progress in our laboratory to identify which promoter elements
and transcription factors are involved in lyso-PCinduced
endothelial gene upregulation.
In summary, we have demonstrated that PDGF-B protein expression is
upregulated by lyso-PC and have partially characterized potential
signal transduction mechanisms responsible for
endothelial gene induction elicited by lyso-PC; PDGF-B
and ICAM-1 gene induction by lyso-PC appears to depend on signal
transduction mechanisms other than PMA-regulatable PKC, which can be
suppressed by elevated levels of cAMP. Dependence of de novo protein
synthesis for PDGF-B is different from that for ICAM-1, suggesting that
lyso-PC might stimulate multiple and diverse signaling pathways.
Further studies related to signal transduction pathways and
transcriptional regulatory mechanisms involved in this lipid stimulus
relevant to atherogenesis and inflammation may provide new insights
into endothelial activation in these
pathophysiological settings and might provide
potential therapeutic targets in preventing vascular diseases.
 |
Selected Abbreviations and Acronyms
|
|---|
| Bt2cAMP |
= |
dibutyryl cAMP |
| ECGS |
= |
endothelial cell growth supplement |
| FBS |
= |
fetal bovine serum |
| HB-EGF |
= |
heparin-binding epidermal growth factorlike growth factor |
| HUVEC |
= |
human umbilical vein endothelial cell |
| ICAM-1 |
= |
intercellular adhesion molecule-1 |
| IL |
= |
interleukin |
| lyso-PC |
= |
lysophosphatidylcholine |
| PDGF |
= |
platelet-derived growth factor |
| PKC |
= |
protein kinase C |
| PMA |
= |
phorbol 12-myristate 13-acetate |
| TBS |
= |
Tris-buffered saline |
TNF- |
= |
tumor necrosis factor- |
| VCAM-1 |
= |
vascular cell adhesion molecule-1 |
|
 |
Acknowledgments
|
|---|
This study was supported by a research grant from the Ministry
of
Education, Science, and Culture of Japan (No. 06671022) and
a
grant-in-aid from the Japan Research Foundation for Clinical
Pharmacology,
Tokyo, Japan. We thank the doctors and nursing staff in
the
obstetrics ward of Kyoto University Hospital for their help
in
obtaining human umbilical cords. We also gratefully acknowledge
Dr
Tucker Collins (Brigham and Women's Hospital, Boston, Mass)
for his
generous gift of PDGF-B cDNA and helpful discussions.
Received October 24, 1994;
accepted April 19, 1995.
 |
References
|
|---|
-
Gimbrone MA Jr, Kume N, Cybulsky MI.
Vascular endothelial dysfunction and the
pathogenesis of atherosclerosis. In: Weber PC,
Leaf A, eds. Atherosclerosis
Reviews. New York, NY: Raven Press Publishers;
1993;25:1-9.
-
Ross R. The pathogenesis of
atherosclerosis: a perspective for the 1990's.
Nature. 1993;362:801-809. [Medline]
[Order article via Infotrieve]
-
Libby P, Hansson GK. Involvement of immune
system in human atherogenesis: current knowledge and unanswered
questions. Lab Invest. 1991;64:5-15. [Medline]
[Order article via Infotrieve]
-
Witztum JL, Steinberg D. Role of oxidized low
density lipoprotein in atherogenesis. J Clin
Invest. 1991;88:1785-1792.
-
Vadas P, Pruzanski W. Role of secretory
phospholipase A2 in the pathogenesis of disease. Lab
Invest. 1986;55:391-404. [Medline]
[Order article via Infotrieve]
-
Kume N, Cybulsky MI, Gimbrone MA Jr.
Lysophosphatidylcholine, a component of atherogenic
lipoproteins, induces mononuclear adhesion molecules in cultured human
and rabbit arterial endothelial
cells. J Clin Invest. 1992;90:1138-1144.
-
Kume N, Gimbrone MA Jr. Lysophosphatidylcholine
transcriptionally induces growth factor gene expression in cultured
human endothelial cells. J Clin
Invest. 1994;93:907-911.
-
Nakano T, Raines EW, Abraham JA, Klagsbrun M, Ross R.
Lysophosphatidylcholine upregulates the level of heparin-binding
epidermal growth factor-like growth factor mRNA in human
monocytes. Proc Natl Acad Sci U S A. 1994;91:1069-1073. [Abstract/Free Full Text]
-
Kume N, Arai H, Kawai C, Kita T. Receptors for
modified low-density lipoproteins in human endothelial
cells: different recognition for acetylated low-density
lipoprotein and oxidized low-density lipoprotein. Biochim
Biophys Acta. 1991;1091:63-67. [Medline]
[Order article via Infotrieve]
-
Chomczynski P, Sacchi N. Single-step method of
RNA isolation by acid guanidinium thiocyanate-phenol-chloroform
extraction. Anal Biochem. 1987;162:156-159. [Medline]
[Order article via Infotrieve]
-
Simmons D, Makgoba MW, Seed B. ICAM: an adhesion
ligand of LFA-1 is homologous to the neural cell adhesion molecule
NCAM. Nature. 1988;331:624-627. [Medline]
[Order article via Infotrieve]
-
Clarke MF, Westin E, Schmit D, Josephs SF, Ratner L,
Wong-Staal F, Gallo RC, Reitz MS Jr. Transformation of NIH 3T3
cells by a human c-sis cDNA clone.
Nature. 1984;308:464-467. [Medline]
[Order article via Infotrieve]
-
Collins T, Ginsburg D, Boss JM, Orkin H, Pober JS.
Cultured human endothelial cells express
platelet-derived growth factor B chain. Nature. 1985;316:748-750. [Medline]
[Order article via Infotrieve]
-
Raines EW, Ross R. Compartmentalization of PDGF
on extracellular binding sites dependent on exon-6-encoded
sequences. J Cell Biol. 1992;116:533-543. [Abstract/Free Full Text]
-
Kelly JL, Sanchez A, Brown GS, Chesterman CN, Sleigh
MJ. Accumulation of PDGF B and cell-binding forms of PDGF A in
the extracellular matrix. J Cell Biol. 1993;121:1153-1163. [Abstract/Free Full Text]
-
Soyombo AA, DiCorleto PE. Stable expression of
human platelet-derived growth factor B chain by bovine aortic
endothelial cells. J Biol
Chem. 1994;269:17734-17740. [Abstract/Free Full Text]
-
Wertheimer SJ, Myers CL, Wallace RW, Parks TP.
Intercellular adhesion molecule-1 gene expression in human
endothelial cells: differential regulation by tumor
necrosis factor-
and phorbol myristate acetate.
J Biol Chem. 1992;267:12030-12035. [Abstract/Free Full Text]
-
Kugiyama K, Ohgushi M, Sugiyama S, Murohara T, Fukunaga
K, Miyamoto E, Yasue H. Lysophosphatidylcholine inhibits surface
receptormediated intracellular signals in endothelial
cells by a pathway involving protein kinase C activation.
Circ Res. 1992;71:1422-1428. [Abstract/Free Full Text]
-
Sugiyama S, Kugiyama K, Ohgushi M, Fujimoto K, Yasue H.
Lysophosphatidylcholine in oxidized low-density lipoprotein
increases endothelial susceptibility to
polymorphonuclear leukocyteinduced endothelial
dysfunction in porcine coronary arteries.
Circ Res. 1994;74:565-575. [Abstract/Free Full Text]
-
Ritchie AJ, Johnson DR, Ewenstein BM, Pober JS.
Tumor necrosis factor induction of surface antigen is
independent of protein kinase C activation or inactivation: studies
with phorbol myristate acetate and
staurosporine. J Immunol. 1991;146:3056-3062. [Abstract]
-
Myers CL, Desai SN, Schembri-King J, Letts GL, Wallace
RW. Discriminatory effects of protein kinase
inhibitors and calcium ionophore on
endothelial ICAM-1 induction. Am J
Physiol. 1992;262:C365-C373. [Abstract/Free Full Text]
-
Inoue N, Hirata K, Yamada M, Hamamori Y, Matsuda Y,
Akita H, Yokoyama M. Lysophosphatidylcholine inhibits
bradykinin-induced phosphoinositide hydrolysis and
calcium transients in cultured bovine aortic
endothelial cells. Circ
Res. 1992;71:1410-1421. [Abstract/Free Full Text]
-
Daniel TO, Gibbs VC, Milfay DF, Williams LT.
Agents that increase cAMP accumulation block
endothelial c-sis induction by thrombin and
transforming growth factor-ß. J Biol
Chem. 1987;262:11893-11896. [Abstract/Free Full Text]
-
Pober JS, Slowik MR, De Luca LG, Ritchie AJ.
Elevated levels of cyclic AMP inhibits
endothelial cell synthesis and expression of
TNF-induced endothelial-leukocyte adhesion molecule-1,
and vascular cell adhesion molecule-1, but not intercellular adhesion
molecule-1. J Immunol. 1993;150:5114-5123. [Abstract]
-
Ratner L, Thielan B, Collins T. Sequences of 5'
portion of the human c-sis gene: characterization of the
transcriptional promoter and regulation of expression of the protein
product by 5' untranslated mRNA sequence. Nucleic
Acids Res. 1987;15:6017-6036. [Abstract/Free Full Text]
-
Pech M, Rao CD, Robbins KC, Aaronson SA.
Functional identification of regulatory elements within the
promoter region of platelet-derived growth factor 2.
Mol Cell Biol. 1989;9:396-405. [Abstract/Free Full Text]
-
Khachigian LM, Fries JWU, Benz MW, Bonthron DT, Collins
T. Novel cis-acting elements in the human platelet-derived
growth factor B-chain core promoter that mediate gene expression in
cultured vascular endothelial cells.
J Biol Chem. 1994;269:22647-22656. [Abstract/Free Full Text]
-
Degitz K, Lian-Jie L, Caughman SW. Cloning and
characterization of the 5'-transcriptional regulatory region of the
human intercellular adhesion molecule 1 gene. J
Biol Chem. 1991;266:14024-14030. [Abstract/Free Full Text]
-
Voraberger G, Schafer R, Stratowa C. Cloning of
the human gene for intercellular adhesion molecule 1 and
analysis of its 5'-regulatory region: induction by
cytokines and phorbol ester. J
Immunol. 1991;147:2777-2786.[Abstract/Free Full Text]
This article has been cited by other articles:

|
 |

|
 |
 
A. Md Sheikh, H. Ochi, A. Manabe, and J. Masuda
Lysophosphatidylcholine posttranscriptionally inhibits interferon-{gamma}-induced IP-10, Mig and I-Tac expression in endothelial cells
Cardiovasc Res,
January 1, 2005;
65(1):
263 - 271.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Morimoto, N. Kume, S. Miyamoto, Y. Ueno, H. Kataoka, M. Minami, K. Hayashida, N. Hashimoto, and T. Kita
Lysophosphatidylcholine Induces Early Growth Response Factor-1 Expression and Activates the Core Promoter of PDGF-A Chain in Vascular Endothelial Cells
Arterioscler. Thromb. Vasc. Biol.,
May 1, 2001;
21(5):
771 - 776.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Yokoyama, F. Shimizu, and M. Setaka
Simultaneous separation of lysophospholipids from the total lipid fraction of crude biological samples using two-dimensional thin-layer chromatography
J. Lipid Res.,
January 1, 2000;
41(1):
142 - 147.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
E. Nishi, N. Kume, Y. Ueno, H. Ochi, H. Moriwaki, and T. Kita
Lysophosphatidylcholine Enhances Cytokine-Induced Interferon Gamma Expression in Human T Lymphocytes
Circ. Res.,
September 7, 1998;
83(5):
508 - 515.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Sugiyama, K. Kugiyama, N. Ogata, H. Doi, Y. Ota, M. Ohgushi, T. Matsumura, H. Oka, and H. Yasue
Biphasic Regulation of Transcription Factor Nuclear Factor-{kappa}B Activity in Human Endothelial Cells by Lysophosphatidylcholine Through Protein Kinase C–Mediated Pathway
Arterioscler. Thromb. Vasc. Biol.,
April 1, 1998;
18(4):
568 - 576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. T. Wong, K. Tran, G. N. Pierce, A. C. Chan, K. O, and P. C. Choy
Lysophosphatidylcholine Stimulates the Release of Arachidonic Acid in Human Endothelial Cells
J. Biol. Chem.,
March 20, 1998;
273(12):
6830 - 6836.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Hara, T. Shike, N. Takasu, and T. Mizui
Lysophosphatidylcholine Promotes Cholesterol Efflux From Mouse Macrophage Foam Cells
Arterioscler. Thromb. Vasc. Biol.,
July 1, 1997;
17(7):
1258 - 1266.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
E. Nishi, N. Kume, H. Ochi, H. Moriwaki, Y. Wakatsuki, S. Higashiyama, N. Taniguchi, and T. Kita
Lysophosphatidylcholine Increases Expression of Heparin-Binding Epidermal Growth Factor–Like Growth Factor in Human T Lymphocytes
Circ. Res.,
May 19, 1997;
80(5):
638 - 644.
[Abstract]
[Full Text]
|
 |
|